Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q1 FY20 results · Apr–Jun 2019
Aarti Drugs reported revenue from operations of ₹405.43 crore (up 8.3% from Q1 FY19) and net profit of ₹22.45 crore (down 3.9% from Q1 FY19) for Q1 FY20 (Apr–Jun 2019), on a consolidated basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 405.43 | 374.29 | +8.3% | 459.14 | −11.7% |
| Other income | 0.06 | 0.92 | −93.5% | 4.99 | −98.8% |
| Total income | 405.49 | 375.21 | +8.1% | 464.13 | −12.6% |
| Profit before tax | 33.63 | 33.72 | −0.3% | 39.75 | −15.4% |
| Net profit for the period | 22.45 | 23.37 | −3.9% | 27.44 | −18.2% |
| EPS, basic (₹) | 9.56 | 9.82 | −2.6% | 12.06 | −20.7% |
| Net margin (%) | 5.5 | 6.2 | 6.0 |
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 370.02 | 351.55 | +5.3% | 432.54 | −14.5% |
| Other income | 0.10 | 0.92 | −89.1% | 5.03 | −98.0% |
| Total income | 370.12 | 352.47 | +5.0% | 437.57 | −15.4% |
| Profit before tax | 32.32 | 32.39 | −0.2% | 37.51 | −13.8% |
| Net profit for the period | 21.57 | 22.39 | −3.7% | 25.69 | −16.0% |
| EPS, basic (₹) | 9.19 | 9.40 | −2.2% | 11.31 | −18.7% |
| Net margin (%) | 5.8 | 6.4 | 5.9 |
Consolidated
- Filed with BSE
- 27 Jul 2019, 15:23 IST
- Board meeting
- 26 Jul 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jul 2019, 15:23 IST
- Board meeting
- 26 Jul 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Audited
- Source
- XBRL filing on BSE